12960 Federal Register / Vol. 86, No. 42 / Friday, March 5, 2021 / Notices 

Dated: March 1, 2021. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–04595 Filed 3–4–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; NCI Predoc 

to Postdoc Fellow Transition Award (F99/ 

K00). 

Date: March 23–24, 2021. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W604, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Scott A. Chen, Ph.D., 

Scientific Review Officer, Program and 

Review Extramural Staff Training Office, 

Division of Extramural Activities, National 

Cancer Institute, NIH, 9609 Medical Center 

Drive, Room 7W604, Rockville, Maryland 

20850, 240–276–6038, chensc@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: March 1, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–04517 Filed 3–4–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Cancer Institute 

Board of Scientific Advisors. 

The meeting will be held virtually 

and is open to the public. Individuals 

who plan to view the virtual meeting 

and need special assistance or other 

reasonable accommodations to view the 

meeting, should notify the Contact 

Person listed below in advance of the 

meeting. The meeting will be videocast 

and can be accessed from the NIH 

Videocasting and Podcasting Website 

(http://videocast.nih.gov/). 

Name of Committee: National Cancer 

Institute Board of Scientific Advisors. 

Date: March 15, 2021. 

Time: 1:00 p.m. to 5:30 p.m. 

Agenda: Director’s Report; RFA, RFP, and 

PAR Concept Reviews; and Scientific 

Presentations. 

Place: National Cancer Institute—Shady 

Grove, 9609 Medical Center Drive, Rockville, 

MD 20850 (Virtual Meeting). 

Date: March 16, 2021. 

Time: 1:00 p.m. to 5:30 p.m. 

Agenda: RFA, RFP, and PAR Concept 

Reviews; and Scientific Presentations. 

Place: National Cancer Institute—Shady 

Grove, 9609 Medical Center Drive, Rockville, 

MD 20850 (Virtual Meeting). 

Contact Person: Paulette S. Gray, Ph.D., 

Director, Division of Extramural Activities, 

National Cancer Institute—Shady Grove, 

National Institutes of Health, 9609 Medical 

Center Drive, Room 7W444, Bethesda, MD 

20892, 240–276–6340, grayp@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: BSA: http://

deainfo.nci.nih.gov/advisory/bsa/bsa.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

This notice is being published less than 15 

days prior to the meeting due to scheduling 

difficulties. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: March 1, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–04518 Filed 3–4–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; Avenir 

Award Program for Genetics or Epigenetics of 

Substance Use Disorders (DP1 Clinical Trial 

Optional). 

Date: March 11, 2021. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, MSC 6021, Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Person: Ivan K. Navarro, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, Division of 

Extramural Research, National Institute on 

Drug Abuse, NIH, 301 North Stonestreet 

Avenue, MSC 6021, Bethesda, MD 20892, 

(301) 827–5833, ivan.navarro@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: February 26, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–04514 Filed 3–4–21; 8:45 am] 

BILLING CODE 4140–01–P 


jbell on DSKJLSW7X2PROD with NOTICES